Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Castillo JJ, Abeykoon JP, Gustine JN, Zanwar S, Mein K, Flynn CA, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, King R, Yang G, Hunter ZR, Advani RH, Palomba ML, Ansell SM, Gertz MA, Kapoor P, Treon SP. Castillo JJ, et al. Among authors: guerrera ml. Br J Haematol. 2021 Feb;192(3):542-550. doi: 10.1111/bjh.17225. Epub 2020 Nov 18. Br J Haematol. 2021. PMID: 33207010 Free PMC article. Clinical Trial.
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, Meid K, Guerrera ML, Munshi M, Chan G, Chen J, Kofides A, Patterson CJ, Yang G, Liu X, Severns P, Dubeau T, Hunter ZR, Castillo JJ. Treon SP, et al. Among authors: guerrera ml. Br J Haematol. 2018 Feb;180(3):374-380. doi: 10.1111/bjh.15049. Epub 2017 Nov 27. Br J Haematol. 2018. PMID: 29181840 Free article.
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.
Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid K, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. Chen JG, et al. Among authors: guerrera ml. Blood. 2018 May 3;131(18):2047-2059. doi: 10.1182/blood-2017-10-811752. Epub 2018 Mar 1. Blood. 2018. PMID: 29496671 Free article.
MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.
Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR. Guerrera ML, et al. Haematologica. 2018 Sep;103(9):e408-e411. doi: 10.3324/haematol.2018.190181. Epub 2018 Mar 29. Haematologica. 2018. PMID: 29599202 Free PMC article. No abstract available.
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ, Xu L. Gustine JN, et al. Among authors: guerrera ml. Br J Haematol. 2019 Jan;184(2):242-245. doi: 10.1111/bjh.15560. Epub 2018 Sep 5. Br J Haematol. 2019. PMID: 30183082 Free article.
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE, Liu X, Demos MG, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Yang G, Hunter ZR, Treon SP. Castillo JJ, et al. Among authors: guerrera ml. Br J Haematol. 2019 Nov;187(3):356-363. doi: 10.1111/bjh.16088. Epub 2019 Jul 3. Br J Haematol. 2019. PMID: 31267520 Free article.
CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
Gustine JN, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Keezer A, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ. Gustine JN, et al. Among authors: guerrera ml. Blood Adv. 2019 Oct 8;3(19):2800-2803. doi: 10.1182/bloodadvances.2019000635. Blood Adv. 2019. PMID: 31570491 Free PMC article.
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
Sewastianik T, Guerrera ML, Adler K, Dennis PS, Wright K, Shanmugam V, Huang Y, Tanton H, Jiang M, Kofides A, Demos MG, Dalgarno A, Patel NA, Nag A, Pinkus GS, Yang G, Hunter ZR, Jarolim P, Munshi NC, Treon SP, Carrasco RD. Sewastianik T, et al. Among authors: guerrera ml. Blood Adv. 2019 Nov 12;3(21):3360-3374. doi: 10.1182/bloodadvances.2019000588. Blood Adv. 2019. PMID: 31698464 Free PMC article.
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
Castillo JJ, Gustine JN, Keezer A, Meid K, Flynn CA, Dubeau TE, Chan G, Chen J, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Castillo JJ, et al. Among authors: guerrera ml. Am J Hematol. 2020 Apr;95(4):372-378. doi: 10.1002/ajh.25712. Epub 2020 Jan 7. Am J Hematol. 2020. PMID: 31868242 Free article.
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.
Liu X, Chen JG, Munshi M, Hunter ZR, Xu L, Kofides A, Tsakmaklis N, Demos MG, Guerrera ML, Chan GG, Jimenez C, Patterson CJ, Meid K, Keezer A, Castillo JJ, Treon SP, Yang G. Liu X, et al. Among authors: guerrera ml. Blood Adv. 2020 Jan 14;4(1):141-153. doi: 10.1182/bloodadvances.2019000947. Blood Adv. 2020. PMID: 31935288 Free PMC article.
36 results